Answers are grounded in this paper and cite their sources.
Significant disparities persist across racial populations, despite the fact that the management of prostate cancer (PCa) continues to evolve with technological advancements. African American (AA) men face a 1.5-fold higher incidence and 2.2-fold higher mortality from PCa compared with White men, highlighting the urgent need for population-specific approaches in diagnosis and risk stratification.1 In this retrospective study of 149 patients undergoing biparametric MRI, the authors demonstrate that population-specific radiomic models outperformed population-agnostic approaches for distinguishing clinically significant PCa (csPCa) from clinically insignificant disease.2 The main result of the study is that radiomic features associated with csPCa differ substantially between AA and White populations, particularly in peritumoral regions. The AUC of the AA-specific model was 0.84, which is higher than the population-agnostic model's 0.57 (P < .05). In addition, the performance was further improved by the integration of clinical parameters, resulting in an AUC of 0.90. These findings suggest that tumor heterogeneity patterns captured by radiomics may reflect underlying biological differences previously identified at genomic and molecular levels.3 Few previous genomic studies identified differential gene expression patterns between AA and White men,4 and this work extends those observations to imaging phenotypes and align with accumulating evidence of population-specific differences in prostate cancer biology. Most existing AI-based risk stratification tools have been developed without adequate representation from high-risk AA populations, potentially contributing to persistent health fcare disparities. Although larger, multi-institutional cohorts are necessary for validation, this proof-of-concept study offers preliminary evidence that population-specific approaches are worth investigating and addresses a critical gap in PCa radiomics research. If validated prospectively, these approaches could inform population-specific guidelines for biopsy recommendations and treatment planning, ultimately helping to address persistent disparities in prostate cancer care.
No takes yet. Share an insight, caveat, or question.
Tharakeswara Bathala (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: